Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study

[11] Pan TC(2016)Early dissemination seeds metastasis in breast cancer Nature 540 552-30729

[12] Ruth J(2016)Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer Oncotarget 7 24677-210

[13] Feng Y(2020)Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-spy2 adaptively randomized clinical trial JAMA Oncol 6 30715-5397

[14] Zhou A(2015)Approaches to isolation and molecular characterization of disseminated tumor cells Oncotarget 4 31-235

[15] Pant D(2018)Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer NPJ Breast Cancer 1634 203-22

[16] Grimley JS(2017)Enumeration of circulating tumor cells and disseminated tumor cells in blood and bone marrow by immunomagnetic enrichment and flow cytometry (IE/FC) Methods Mol Biol 25 5388-34

[17] Wandless TJ(2019)Synchronous detection of circulating tumor cells in blood and disseminated tumor cells in bone marrow predicts adverse outcome in early breast cancer Clin Cancer Res 14 R117-1060

[18] Demichele A(2012)Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival Breast Cancer Res 100 229-undefined

[19] Trial Investigators ISPY(2006)REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 375 11-undefined

[20] Chodosh LA(2016)Adaptive randomization of neratinib in early breast cancer N Engl J Med 375 23-undefined

[11] Pan TC(2016)Early dissemination seeds metastasis in breast cancer Nature 540 552-30729

[12] Ruth J(2016)Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer Oncotarget 7 24677-210

[13] Feng Y(2020)Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-spy2 adaptively randomized clinical trial JAMA Oncol 6 30715-5397

[14] Zhou A(2015)Approaches to isolation and molecular characterization of disseminated tumor cells Oncotarget 4 31-235

[15] Pant D(2018)Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer NPJ Breast Cancer 1634 203-22

[16] Grimley JS(2017)Enumeration of circulating tumor cells and disseminated tumor cells in blood and bone marrow by immunomagnetic enrichment and flow cytometry (IE/FC) Methods Mol Biol 25 5388-34

[17] Wandless TJ(2019)Synchronous detection of circulating tumor cells in blood and disseminated tumor cells in bone marrow predicts adverse outcome in early breast cancer Clin Cancer Res 14 R117-1060

[18] Demichele A(2012)Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival Breast Cancer Res 100 229-undefined

[19] Trial Investigators ISPY(2006)REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 375 11-undefined

[20] Chodosh LA(2016)Adaptive randomization of neratinib in early breast cancer N Engl J Med 375 23-undefined